Biaffin

Newsletter

kinases protein kinase inhibitors signaling activators kinase substrates antibodies bioluminescence assays
ActiveMax® Recombinant Human VEGF121 (HPLC-verified) , 20µg  

ActiveMax® Recombinant Human VEGF121 (HPLC-verified) , 20µg

ActiveMax® Recombinant Human VEGF121 (ActiveMax® Human VEGF121) Ala 27 - Arg 147 was produced in human 293 cells (HEK293)

Synonym: VEGF121, VEGFA, RP1-261G23.1, MGC70609, MVCD1, VPF, vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, VEGF protein

More details

VE1-H4213-020

Availability: within 7 days

238,00 €

Background: Vascular endothelial growth factor (VEGF), also known as vascular permeability factor (VPF) and VEGF-A, and is a member of the platelet-derived growth factor (PDGF)/vascular endothelial growth factor (VEGF) family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. Alternatively spliced isoforms of 121,145,165,183,189 and 206 amino acids in length are expressed in humans. VEGF165 appears to be the most abundant and potent isoform, followed by VEGF121 and VEGF189 [1, 2]. VEGF121 is the only form that lacks a basic heparinbinding region and is freely diffusible [4]. Mouse embryos expressing only the corresponding isoform (VEGF120) do not survive to term, and show defects in skeletogenesis [5]. Human VEGF121 shares 87% aa sequence identity with corresponding regions of mouse and rat, 93% with feline, equine and bovine, and 91%, 95% and 96% with ovine, canine and porcine VEGF, respectively. VEGF121 induces the proliferation of lymphatic endothelial cells. The lymphangiogenesis may be promoted by upregulation of VEGF121, which may in turn act in part via induction of VEGF-C.

Source
ActiveMax® Recombinant Human VEGF121 (ActiveMax® Human VEGF121) Ala 27 - Arg 147 (Accession # NP_001020541) was produced in human 293 cells (HEK293)

Molecular Characterization
ActiveMax® Human VEGF121 contains no "tag", and has a calculated MW of 14 kDa (monomer). The predicted N-terminus is Ala 27. As a result of glycosylation, the reducing (R) protein migrates as 19 kDa (monomer), and the non-reducing (NR) protein migrates as 40 kDa (homodimer) in SDS-PAGE .

Endotoxin
Less than 1.0 EU per μg of the ActiveMax® Human VEGF121 by the LAL method.

Purity
>95% as determined by SDS-PAGE.
>90% as determined by SEC-HPLC.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Measured by its binding ability in a functional ELISA.
Immobilized ActiveMax® Human VEGF121 (Catalog # VE1-H4213) at 2 μg/mL can bind Human VEGF R2, Strep Tag (Catalog # KDR-H5280) with a linear range of 0.15-2.5 μg/mL.

References

(1) Byrne, A.M. et al., 2005, J. Cell. Mol. Med, 9(4):777-94.
(2) Robinson, C.J. et al., 2001, J. Cell. Sci. 114(Pt 5):853-65.
(3) Zelzer, E. et al., 2002, Development, 129(8):1893-904.